Surmodics, Inc.
SRDX
Get informed when a big investor buys or sells
+ FollowMarket Cap$614.51M
Close$
$0.82
98.1% downside
Current Fair Value
98.1% downsideOvervalued by 98.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $614.51 Million |
|---|---|
| Enterprise Value | $621.66 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.82 |
| Beta | 1.39 |
| Outstanding Shares | 14,281,000 |
Return
| Return on Equity | -15.84% |
|---|---|
| Return on Assets | -10.38% |
| Return on Invested Capital | -11.77% |
Valuation & Multiples
| P/E Ratio | -43.29 |
|---|---|
| PEG | 146.26 |
| Price to Sales | 5.37 |
| Price to Book Ratio | 6.14 |
| Enterprise Value to Revenue | 5.15 |
| Enterprise Value to EBIT | -35.13 |
| Enterprise Value to Net Income | -36 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.3 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
April 28, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.2099▼ 84.44% |
|---|---|
| Total Calls | 169,100▲ 64.17% |
| Total Puts | 204,600▼ 3.31% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 80.85%▼ 4.91% |
|---|---|
| Total Invested | $345.17M▼ 5.15% |
| Investors Holding | 155▲ 14.00% |
ESG Score
No data
About Surmodics, Inc.
CEO: Gary Maharaj Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Surmodics is pursuing hi...